Results 141 to 150 of about 1,716,661 (233)

Receptor binding properties and antinociceptive effects of chimeric peptides consisting of a μ-opioid receptor agonist and an ORL-1 receptor antagonist [PDF]

, 2006
Receptor binding properties and antinociceptive activities of chimeric peptides linked by spacers were investigated. The peptides consisted of the μ-opioid receptor ligand dermorphin (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH_2) or its analog YRFB (Tyr-D-Arg-Phe ...
安保, 明博, Sasaki, Yusuke, Ito, Risa, イトウ, リサ, ニシヤマ, ミハル, 久保, 麻衣, 佐々木, 有亮, 伊藤, 里沙, アンボ, アキヒロ, Nishiyama, Miharu, Ambo, Akihiro, マツシマ, トモコ, ササキ, ユウスケ, 西山, 美春, 河野, 奨, Kubo, Mai, Matsushima, Tomoko, カワノ, ススム, Kawano, Susumu, クボ, マイ, 松島, 知子   +20 more
core  

TROP2‐Targeting Chimeras (TRTACs) for Tumor Cell‐Selective Membrane Protein Degradation and Enhanced Drug Delivery

Advanced Science, EarlyView.
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen, Xinying Fu, Wenqian Dong, Xiaobei Deng, Simin Chen, Fujun Wang, Jian Zhao, Shiqun Shao, Liqiang Fan, Jingyu Zhang, Lixin Zhang   +10 more
wiley   +1 more source

SPRED2 Negatively Regulates CD8+ T Cell‐Mediated Antitumor Immunity in Breast Cancer

Advanced Science, EarlyView.
Sprouty‑related EVH1 domain containing 2 (SPRED2) restrains Ras/Raf/ERK signaling in CD8+ T cells. Host SPRED2 deficiency enhances T‐cell survival, cytotoxicity, and memory‐like phenotypes, reducing primary tumor growth and endpoint lung metastatic burden in breast cancer models.
Miao Tian, Teizo Yoshimura, Kun Zhao, Chunning Li, Tong Gao, Ziyi Wang, Masayoshi Fujisawa, Toshiaki Ohara, Akihiro Matsukawa   +8 more
wiley   +1 more source

Chimeric Antigen Receptor Therapy for B-cell Malignancies

Journal of Cancer, 2011
We presented data showing that the CART-19 cells expressing the 4-1BB signaling domain can have unprecedented and massive in-vivo expansion, traffic to tumor sites, persist long term in vivo, and induce rapid and potent anti-tumor activity in ...
David L Porter, Michael Kalos, Zhaohui Zheng, Bruce Levine, Carl June
doaj  

The potential and promise for clinical application of adoptive T cell therapy in cancer

Journal of Translational Medicine
Adoptive cell therapy has revolutionized cancer treatment, especially for hematologic malignancies. T cells are the most extensively utilized cells in adoptive cell therapy.
Yinqi Li, Yeteng Zheng, Taiqing Liu, Chuanyun Liao, Guobo Shen, Zhiyao He   +5 more
doaj   +1 more source

CEA-Specific Next-Generation Chimeric Antigen Receptor-Engineered NK-92 Cells Effective in Colorectal Cancer Models

CEA-SPECIFIC NEXT-GENERATION CHIMERIC ANTIGEN RECEPTOR-ENGINEERED NK-92 CELLS EFFECTIVE IN COLORECTAL CANCER MODELS CEA-Specific Next-Generation Chimeric Antigen Receptor-Engineered NK-92 Cells Effective in Colorectal Cancer Models / Franzén, Alexander ...
Franzén, Alexander Sebastian
core  

Degrading GPX4 via Biomimetic Nanoparticle‐Mediated In Situ Synthesis of Deep‐Learning‐Designed Binder‐Degron Chimeras for Prostate Cancer Therapy

Advanced Science, EarlyView.
A deep‐learning‐designed binder is fused to a combinatorial degron to create a binder‐degron chimera (bdC) that recruits the CUL2‐RING ubiquitin ligase complex. Encapsulation in a prostate‐cancer‐targeted, CD47‐camouflaged nanocarrier enables tumor‐specific in situ bdC expression, triggering GPX4 degradation and ferroptosis, thereby establishing a ...
Si‐Han Zhang, Ye An, Na Zeng, Mei‐Cheng Liu, Jian‐Xuan Sun, Xi Gong, Jin‐Zhou Xu, Shao‐Gang Wang, Qi‐Dong Xia   +8 more
wiley   +1 more source

In Situ Bioorthogonal Synthesis of PROTACs via Dual‐Responsive Cleavage for Synergistic Photo‐Immunotherapy

Advanced Science, EarlyView.
A bioactive self‐delivering SNAP‐TAC platform responds to tumor‐associated cathepsin B and glutathione, enabling in situ bioorthogonal synthesis of a BRD4‐degrading proteolysis‐targeting chimera within the tumor microenvironment. The resulting BRD4 degradation and PD‐L1 downregulation synergize with photodynamic therapy‐induced immunogenic cell death ...
Shiqin Jian, Jiasha Wu, Fusheng Xu, Yan Zuo, Huaxing Shen, Rui Ji, Luyi Wang, Na Li, Yanting Sun, Yongsheng Yu, Yejiao Shi, Honggang Hu, Feng Xu, Dan Huang, Xiaochun Hu   +14 more
wiley   +1 more source

Engineered Peptide Self‐Assembled Nanofibers for Enhanced STING Activation: A Promising Nanodelivery Platform for Immunotherapy of Pediatric Solid Tumors

Advanced Science, EarlyView.
An engineered peptide self‐assembled nanofiber platform, designed to replicate STING–cGAMP binding motifs, facilitates pH‐responsive cytosolic delivery of cGAMP, enhances the endoplasmic reticulum with high efficiency, and robustly activates the STING pathway.
Yubin He, Xiao Lu, Chang qing Yang, Ran Zhang, Bo Wan, Xin Ni, Dong Mei   +6 more
wiley   +1 more source

MN•CS•IO System: Cross‐Species Study for HBB Function in High‐Altitude Hypoxia Adaptation

Advanced Science, EarlyView.
We developed an integrative mesh‐nanorod sorting, chitosan nanoparticle delivery, and intraosseous injection (MN•CS•IO) system to investigate HBB in high‐altitude hypoxia adaptation. Transplanting Tibetan animals' HBB‐modified Lin‐ cells into mice achieved 95.59% transfection efficiency and 8.15% HBB expression. High‐altitude HBB recipients upregulated
Wenqiao Hui, Lin Mao, Binggang Li, Hanyue Kang, Zhengquan Tang, Sheng Chen, Hui Yang, Yu Qiao, Huiqian Ding, Yuhuan Wang, Min Li, Junjie Hu, Shoudong Ye, Xin Wang, Xiaobin Xu, Yupeng Wang, Tana Wuren, Qian Ban, Baowei Zhang   +18 more
wiley   +1 more source